Boston Pharmaceuticals
WHO WE ARE WHAT WE DO PIPELINE CLINICAL TRIALS PARTNERING NEWS CAREERS
WHO WE AREWHAT WE DOPIPELINECLINICAL TRIALSPARTNERINGNEWSCAREERS
Boston Pharmaceuticals
Scroll
 
 

NEWS ARCHIVE

 
 
Boston-AdobeStock_2.jpeg
 
 

2018

10/3/2018

Boston Pharmaceuticals Acquires Three Novel Anti-Infective Programs from Novartis

10/3/2018

Boston Pharmaceuticals Adds Five New Drug Programs to Its Pipeline in Licensing Deal

2/6/2018

Boston Pharmaceuticals to Present at 2018 BIO CEO & Investor Conference

1/4/2018

Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Selective Potassium Channel Blocker for Atrial Fibrillation

2017

8/28/2017

Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors

2015

11/19/2015

Former Sanofi chief to launch Boston Phamaceuticals with $600m

11/19/2015

Viehbacher’s $2B biotech fund wagers $600M on an R&D upstart

11/19/2015

Ex-Sanofi CEO drug hunting with $600M

 
Back to news
 
 
News Archive
archive
 

Boston Pharmaceuticals
55 Cambridge Parkway
Suite 401
Cambridge, MA 02142

info@bostonpharmaceuticals.com
clinicaltrials@bostonpharmaceuticals.com
partnering@bostonpharmaceuticals.com

©2025. Boston Pharmaceuticals. All Rights Reserved.
Legal Notice   |   Privacy Policy